Wednesday, June 26th, 2019


A full text version of this article is available.
To access article obtain online access here or login
Lymphoid Infiltrate and ERG Status in Prostatic Carcinoma
Authors:  Katarzyna Miłek, M.S., Joanna Szpor, M.D., Ph.D., Katarzyna Ewa Tyrak, M.D., Łukasz Bełch, M.D., Piotr Chłosta, M.D., Ph.D., and Krzysztof Okon, M.D., Ph.D.
  Objective: To analyze the populations of prostatic carcinoma lymphoid cells in context of ERG expression.
Study Design:
The material of the study consisted of 122 radical prostatectomy specimens. Immunohistochemistry for CD20, CD45RO, CD4, CD8, and CD56 was performed in a routine manner and the immunopositive cells were counted in the intratumoral, peritumoral, and extratumoral compartments.
A total of 67 cases were ERG-positive. They tended to show higher counts of immune cells in comparison to ERG-negative cases, with the highest differences for CD56 as well as intratumoral CD8 cells. CD56 cells were also more numerous in high-grade tumors, similar to CD45RO cells, which were more prominent in cancers with extraprostatic extension.
With regard to the measured parameters, the counts of lymphoid cells in the ERG-negative group were lower than those in the ERG-positive group but did not reach statistical significance.
Keywords:  immunohistochemistry, leukocyte common antigens, lymphocytes, male, prostate cancer, prostate-specific antigen, prostatectomy, prostatic neoplasms
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from